PolarityTE, Inc., a biotechnology and regenerative biomaterials company, focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine and Contract Services. It offers SkinTE, a tissue product for treatment of defects of the skin, as well as contract research services. The company also develops OsteoTE, an autologous homologous bone regeneration product; and CartTE, an autologous cartilage regeneration product. In addition, it develops AdipoTE to optimize the delivery of autologous fat; AngioTE for vascular regeneration; NeuralTE for peripheral nerve injuries of the extremities, as well as for patients with neuromas or chronic compression due to joint replacements, migraines, craniofacial injuries, carpal tunnel syndrome, and those who have undergone hernia or abdominal-based procedures; UroTE for the delivery of autologous urogenital epithelium and submucosa; LiverTE to address various causes of liver failure; and BowelTE to deliver an optimized autologous construct to aid in the regeneration of bowel tissue. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone385-237-2279
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.56 million
Profitability
Miscellaneous
Employees123
Next Earnings DateN/A
OptionableOptionable
Polarityte (NASDAQ:PTE) Frequently Asked Questions
What is Polarityte's stock symbol?
Polarityte trades on the NASDAQ under the ticker symbol "PTE."
How were Polarityte's earnings last quarter?
Polarityte Inc (NASDAQ:PTE) released its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.87) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.01) by $0.14. The business had revenue of $1.40 million for the quarter, compared to the consensus estimate of $1.41 million. During the same quarter last year, the firm earned ($0.86) EPS. View Polarityte's Earnings History.
What price target have analysts set for PTE?
7 brokerages have issued 12 month price objectives for Polarityte's stock. Their forecasts range from $3.00 to $26.00. On average, they anticipate Polarityte's stock price to reach $12.86 in the next twelve months. This suggests a possible upside of 708.6% from the stock's current price. View Analyst Price Targets for Polarityte.
What is the consensus analysts' recommendation for Polarityte?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Polarityte in the last year. There are currently 1 sell rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Polarityte.
Has Polarityte been receiving favorable news coverage?
Media coverage about PTE stock has been trending somewhat negative on Sunday, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Polarityte earned a media sentiment score of -1.8 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Polarityte.
Who are some of Polarityte's key competitors?
Some companies that are related to Polarityte include Windtree Therapeutics (WINT), Fennec Pharmaceuticals (FENC), Brainstorm Cell Therapeutics (BCLI), Solid Biosciences (SLDB), Dyadic International (DYAI), X4 Pharmaceuticals (XFOR), Erytech Pharma (ERYP), Gamida Cell (GMDA), Axcella Health (AXLA), Cidara Therapeutics (CDTX), Applied Genetic Technologies (AGTC), Surface Oncology (SURF), Champions Oncology (CSBR), Pluristem Therapeutics (PSTI) and Pharmacyte Biotech (PMCB).
What other stocks do shareholders of Polarityte own?
Who are Polarityte's key executives?
Polarityte's management team includes the folowing people:
- Dr. Denver M. Lough, Chairman, CEO and Chief R&D Officer (Age 38)
- Mr. Paul Elliot Mann, Chief Financial Officer
- Mr. Richard Hague, Chief Operating Officer (Age 59)
- Dr. David Blum, Chief Design & Technology Officer
- Mr. Nikolai Sopko, Chief Scientific Officer and VP of R&D
Who are Polarityte's major shareholders?
Polarityte's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.88%), Levin Capital Strategies L.P. (0.35%), Renaissance Technologies LLC (0.27%), Private Advisor Group LLC (0.23%), Comprehensive Portfolio Management LLC (0.22%) and Cambridge Investment Research Advisors Inc. (0.20%). Company insiders that own Polarityte stock include Cameron J Hoyler, David B Seaburg, Denver Lough, Edward Winslow Swanson, Paul Elliot Mann, Peter A Cohen, Rainer M Erdtmann, Richard Hague and Steve Gorlin. View Institutional Ownership Trends for Polarityte.
Which major investors are selling Polarityte stock?
PTE stock was sold by a variety of institutional investors in the last quarter, including Janney Montgomery Scott LLC, Geode Capital Management LLC and Oppenheimer & Co. Inc.. Company insiders that have sold Polarityte company stock in the last year include Cameron J Hoyler, David B Seaburg, Denver Lough, Paul Elliot Mann, Rainer M Erdtmann, Richard Hague and Steve Gorlin. View Insider Buying and Selling for Polarityte.
Which major investors are buying Polarityte stock?
PTE stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Levin Capital Strategies L.P., Private Advisor Group LLC, Capital Wealth Alliance LLC, Comprehensive Portfolio Management LLC, Bernardo Wealth Planning LLC, UBS Group AG and Cambridge Investment Research Advisors Inc.. Company insiders that have bought Polarityte stock in the last two years include Edward Winslow Swanson, Paul Elliot Mann, Peter A Cohen and Rainer M Erdtmann. View Insider Buying and Selling for Polarityte.
How do I buy shares of Polarityte?
Shares of PTE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Polarityte's stock price today?
One share of PTE stock can currently be purchased for approximately $1.59.
How big of a company is Polarityte?
What is Polarityte's official website?
How can I contact Polarityte?
Polarityte's mailing address is 123 NORTH WRIGHT BROTHERS DRIVE, SALT LAKE CITY UT, 84116. The company can be reached via phone at 385-237-2279 or via email at [email protected]
MarketBeat Community Rating for Polarityte (NASDAQ PTE)
MarketBeat's community ratings are surveys of what our community members think about Polarityte and other stocks. Vote "Outperform" if you believe PTE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTE will underperform the S&P 500 over the long term. You may vote once every thirty days.
